Press Release European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process Jul 7
Press Release Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 Jul 2